• Bed expansion plans: Fortis added 750 beds in the previous financial year and targets adding around 500 brownfield beds annually alongside selective greenfield and acquisition opportunities.
• Diagnostic segment outlook: Agilus Diagnostics is targeting double-digit revenue growth and EBITDA margins above 25% within two to three years, supported by expansion in core metro markets and high-growth segments like genomics.
• ARPOB growth levers: Average revenue per occupied bed is projected to rise through a 2% annual price increase and an additional 2% to 3% from high-end specialty mix additions like oncology and robotic surgeries.
• Capex and funding: The company plans an annual CAPEX of ₹800 to ₹900 crore against a minimum 15% IRR hurdle rate, supported by comfortable leverage at 1.09 times EBITDA and potential ₹10,000 crore growth funding from parent IHH.